Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials.

Kristian ReichM S de Bruin-WellerM DeleuranBrian M CalimlimN ChenX HuA R TenorioJonathan Ian Silverberg

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Greater degrees of clinical responses are related to more robust improvements across multiple dimensions impacted by AD, including itch, skin pain, sleep, anxiety, depression, and QoL.

Keyphrases

patient reported
atopic dermatitis
sleep quality
chronic pain
depressive symptoms
physical activity
pain management
soft tissue
spinal cord